[Studies of guben quyu No I combined with chemotherapy in treating cancer] NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[Studies of guben quyu No I combined with chemotherapy in treating cancer]

Chung Kuo Chung Hsi I Chieh Ho Tsa Chih. 1994 Jul;14(7):392-5. Unique Identifier : AIDSLINE MED/95037543
Yu RC; Peng XM; Rao XQ; Beijing Hospital of TCM.

Abstract: Cancer patients with Qi-Deficiency and Blood Stasis (QDBS) syndrome were studied, and stress was put on the observation of the Guben Quyu No. I, which was used in combining with chemotherapy for synergistic effect and attenuation of toxicity. The results: QDBS syndrome often existed in cancer patients, and chemotherapy exacerbate the occurrence rate of QDBS syndrome. QDBS syndrome is somehow related to immuno-deficiency and blood hypercoagulability, the method of Yiqi Huoxue (YQHX) which used to be combined with chemotherapy could not only reduce the toxic-side effects of chemotherapy, but also improve the cellular immune function and hemorheology. Since the cellular immuno-deficiency and blood hypercoagulability were associated with recurrence and metastasis of cancer. It is considered that the Guben Quyu No I possibly is to reduce the occurring of the above-mentioned consequences.
Keywords: Adult Aged Antineoplastic Agents, Combined/*THERAPEUTIC USE Breast Neoplasms/*DRUG THERAPY/IMMUNOLOGY Cyclophosphamide/ADMINISTRATION & DOSAGE CD4-CD8 Ratio Doxorubicin/ADMINISTRATION & DOSAGE Drugs, Chinese Herbal/*ADMINISTRATION & DOSAGE English Abstract Female Fluorouracil/ADMINISTRATION & DOSAGE Gastrointestinal Neoplasms/*DRUG THERAPY/IMMUNOLOGY Human Lung Neoplasms/*DRUG THERAPY/IMMUNOLOGY Male Middle Age Mitomycin C/ADMINISTRATION & DOSAGE CLINICAL TRIAL JOURNAL ARTICLEKWDadultagedantineoplasticagents,combined/KWDtherapeuticusebreastneoplasms/KWDdrugtherapy/immunologycyclophosphamide/administration&dosagecd4-cd8ratiodoxorubicin/administration&dosagedrugs,chineseherbal/KWDadministration&dosageenglishabstractfemalefluorouracil/administration&dosagegastrointestinalneoplasms/KWDdrugtherapy/immunologyhumanlungneoplasms/KWDdrugtherapy/immunologymalemiddleagemitomycinc/administration&dosageclinicaltrialjournalarticle
950228
M9520858

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .